Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Biohaven
Sort By
Newest First
1 / 1
1 / 1
Migraine
Biohaven Announces NURTEC® ODT Receives First Global Approval Outside the U.S. For Prevention of Migraine
Biohaven
PR-M12-21-01
Dec 13, 2021
Pharma Marketing
Biohaven Recruits Khloe Kardashian for Migraine Campaign
Biohaven
PR-M07-20-NI-025
Jul 16, 2020
Biohaven to Advance Vazegepant Into Phase 3 for Acute Migraine Treatment
Biohaven
PA1632
Mar 27, 2020
Clinical Results
Biohaven Achieves Positive Topline Results for Intranasal Migraine Treatment
Biohaven
PR-M12-19-NI-025
Dec 17, 2019
Investment
Biohaven Announces Closing Of $144M Public Offering Of Common Shares, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
Biohaven
PR-M12-18-NI-084
Dec 28, 2018
Public Offering
Biohaven Announces Proposed Public Offering of Common Shares
Biohaven
PR-M12-18-NI-060
Dec 18, 2018
Clinical Results
Biohaven Reports Positive Results From Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety
Biohaven
PR-M09-18-NI-060
Sep 20, 2018
Bioequivalence Study
Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet
Biohaven
PR-M01-18-NI-034
Jan 12, 2018
